vs

Side-by-side financial comparison of Elastic N.V. (ESTC) and EXELIXIS, INC. (EXEL). Click either name above to swap in a different company.

EXELIXIS, INC. is the larger business by last-quarter revenue ($598.7M vs $423.5M, roughly 1.4× Elastic N.V.). EXELIXIS, INC. runs the higher net margin — 40.8% vs -12.1%, a 53.0% gap on every dollar of revenue. On growth, Elastic N.V. posted the faster year-over-year revenue change (15.9% vs 5.6%). EXELIXIS, INC. produced more free cash flow last quarter ($332.4M vs $26.0M). Over the past eight quarters, EXELIXIS, INC.'s revenue compounded faster (18.7% CAGR vs 13.6%).

Elastic is a Dutch-American software company that provides a platform for enterprise search, observability, and cybersecurity. Its product enables users to search and analyze large-scale data, monitor system performance, and detect anomalies. Originally known as Elasticsearch, the company was founded in 2012 in Amsterdam, Netherlands, and has maintained its operational headquarters in both the Netherlands and San Francisco, California, US. Elastic is publicly traded on the New York Stock Exch...

Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.

ESTC vs EXEL — Head-to-Head

Bigger by revenue
EXEL
EXEL
1.4× larger
EXEL
$598.7M
$423.5M
ESTC
Growing faster (revenue YoY)
ESTC
ESTC
+10.3% gap
ESTC
15.9%
5.6%
EXEL
Higher net margin
EXEL
EXEL
53.0% more per $
EXEL
40.8%
-12.1%
ESTC
More free cash flow
EXEL
EXEL
$306.4M more FCF
EXEL
$332.4M
$26.0M
ESTC
Faster 2-yr revenue CAGR
EXEL
EXEL
Annualised
EXEL
18.7%
13.6%
ESTC

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
ESTC
ESTC
EXEL
EXEL
Revenue
$423.5M
$598.7M
Net Profit
$-51.3M
$244.5M
Gross Margin
75.9%
95.6%
Operating Margin
-1.9%
39.3%
Net Margin
-12.1%
40.8%
Revenue YoY
15.9%
5.6%
Net Profit YoY
-101.5%
74.8%
EPS (diluted)
$-0.48
$0.89

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESTC
ESTC
EXEL
EXEL
Q1 26
$598.7M
Q4 25
$423.5M
$597.8M
Q3 25
$415.3M
$568.3M
Q2 25
$388.4M
$555.4M
Q1 25
$382.1M
$566.8M
Q4 24
$365.4M
Q3 24
$347.4M
$539.5M
Q2 24
$335.0M
$637.2M
Net Profit
ESTC
ESTC
EXEL
EXEL
Q1 26
$244.5M
Q4 25
$-51.3M
$193.6M
Q3 25
$-24.6M
$184.8M
Q2 25
$-16.4M
$159.6M
Q1 25
$-17.1M
$139.9M
Q4 24
$-25.4M
Q3 24
$-49.2M
$118.0M
Q2 24
$-41.1M
$226.1M
Gross Margin
ESTC
ESTC
EXEL
EXEL
Q1 26
95.6%
Q4 25
75.9%
96.9%
Q3 25
76.7%
96.6%
Q2 25
74.8%
96.5%
Q1 25
74.6%
96.5%
Q4 24
74.5%
Q3 24
73.6%
96.8%
Q2 24
73.8%
97.2%
Operating Margin
ESTC
ESTC
EXEL
EXEL
Q1 26
39.3%
Q4 25
-1.9%
39.6%
Q3 25
-2.3%
37.6%
Q2 25
-3.1%
33.6%
Q1 25
-1.2%
28.8%
Q4 24
-1.2%
Q3 24
-9.7%
25.2%
Q2 24
-13.6%
43.3%
Net Margin
ESTC
ESTC
EXEL
EXEL
Q1 26
40.8%
Q4 25
-12.1%
32.4%
Q3 25
-5.9%
32.5%
Q2 25
-4.2%
28.7%
Q1 25
-4.5%
24.7%
Q4 24
-7.0%
Q3 24
-14.2%
21.9%
Q2 24
-12.3%
35.5%
EPS (diluted)
ESTC
ESTC
EXEL
EXEL
Q1 26
$0.89
Q4 25
$-0.48
$0.69
Q3 25
$-0.23
$0.65
Q2 25
$-0.15
$0.55
Q1 25
$-0.16
$0.47
Q4 24
$-0.25
Q3 24
$-0.48
$0.40
Q2 24
$-0.35
$0.77

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESTC
ESTC
EXEL
EXEL
Cash + ST InvestmentsLiquidity on hand
$1.4B
$1.1B
Total DebtLower is stronger
$570.3M
Stockholders' EquityBook value
$891.1M
$2.2B
Total Assets
$2.5B
$2.8B
Debt / EquityLower = less leverage
0.64×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESTC
ESTC
EXEL
EXEL
Q1 26
$1.1B
Q4 25
$1.4B
$988.5M
Q3 25
$1.5B
$791.1M
Q2 25
$1.4B
$1.0B
Q1 25
$584.0M
$1.1B
Q4 24
$658.5M
Q3 24
$594.9M
$1.2B
Q2 24
$1.1B
$1.0B
Total Debt
ESTC
ESTC
EXEL
EXEL
Q1 26
Q4 25
$570.3M
Q3 25
$570.0M
Q2 25
$569.7M
Q1 25
$569.4M
Q4 24
$569.2M
Q3 24
$568.9M
Q2 24
$568.6M
Stockholders' Equity
ESTC
ESTC
EXEL
EXEL
Q1 26
$2.2B
Q4 25
$891.1M
$2.2B
Q3 25
$971.4M
$2.0B
Q2 25
$927.2M
$2.1B
Q1 25
$859.1M
$2.2B
Q4 24
$811.5M
Q3 24
$759.4M
$2.3B
Q2 24
$738.2M
$2.1B
Total Assets
ESTC
ESTC
EXEL
EXEL
Q1 26
$2.8B
Q4 25
$2.5B
$2.8B
Q3 25
$2.5B
$2.7B
Q2 25
$2.6B
$2.8B
Q1 25
$2.3B
$2.9B
Q4 24
$2.2B
Q3 24
$2.2B
$3.0B
Q2 24
$2.2B
$2.8B
Debt / Equity
ESTC
ESTC
EXEL
EXEL
Q1 26
Q4 25
0.64×
Q3 25
0.59×
Q2 25
0.61×
Q1 25
0.66×
Q4 24
0.70×
Q3 24
0.75×
Q2 24
0.77×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESTC
ESTC
EXEL
EXEL
Operating Cash FlowLast quarter
$26.6M
$333.5M
Free Cash FlowOCF − Capex
$26.0M
$332.4M
FCF MarginFCF / Revenue
6.1%
55.5%
Capex IntensityCapex / Revenue
0.1%
0.2%
Cash ConversionOCF / Net Profit
1.36×
TTM Free Cash FlowTrailing 4 quarters
$302.3M
$875.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESTC
ESTC
EXEL
EXEL
Q1 26
$333.5M
Q4 25
$26.6M
$290.3M
Q3 25
$104.8M
$49.0M
Q2 25
$87.0M
$211.4M
Q1 25
$88.1M
$240.3M
Q4 24
$38.4M
Q3 24
$52.8M
$271.3M
Q2 24
$60.9M
$119.5M
Free Cash Flow
ESTC
ESTC
EXEL
EXEL
Q1 26
$332.4M
Q4 25
$26.0M
$288.8M
Q3 25
$104.2M
$46.2M
Q2 25
$84.9M
$208.5M
Q1 25
$87.3M
$236.3M
Q4 24
$37.7M
Q3 24
$52.0M
$263.1M
Q2 24
$60.1M
$113.0M
FCF Margin
ESTC
ESTC
EXEL
EXEL
Q1 26
55.5%
Q4 25
6.1%
48.3%
Q3 25
25.1%
8.1%
Q2 25
21.8%
37.5%
Q1 25
22.8%
41.7%
Q4 24
10.3%
Q3 24
15.0%
48.8%
Q2 24
17.9%
17.7%
Capex Intensity
ESTC
ESTC
EXEL
EXEL
Q1 26
0.2%
Q4 25
0.1%
0.2%
Q3 25
0.2%
0.5%
Q2 25
0.5%
0.5%
Q1 25
0.2%
0.7%
Q4 24
0.2%
Q3 24
0.2%
1.5%
Q2 24
0.3%
1.0%
Cash Conversion
ESTC
ESTC
EXEL
EXEL
Q1 26
1.36×
Q4 25
1.50×
Q3 25
0.27×
Q2 25
1.32×
Q1 25
1.72×
Q4 24
Q3 24
2.30×
Q2 24
0.53×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESTC
ESTC

Self Managed Subscription$192.0M45%
Saa S Self Managed Annual$156.9M37%
Saa S Self Managed Monthly$48.8M12%
Professional Services$25.8M6%

EXEL
EXEL

Cabometyx$544.7M91%
Collaboration$52.1M9%
Collaborative Arrangementwith Takeda$5.9M1%
Cometriq$1.8M0%

Related Comparisons